Company Update: SK pharmteco to Expand Capabilities with Acquisition of Controlling Interest in CBM | Learn More
Logo yposkesi
waves image

Meet our team at Advanced Therapies: March 19-20, 2024 in London, UK.

The event

The Advanced Therapies conference will take place March 19-20, 2024 at the ExCel, London.

Schedule a meeting

Our team

Meet our team during the event: 

Stop by our booth #53 to meet our team during the Phacilitate Advanced Therapies week US and learn more about our extended services to bring your cell and gene therapies to life… SK pharmteco is assembling the most accomplished cell and gene therapy experts in the world, armed with cutting-edge and innovative technologies, to offer scalable, end-to-end, best-in-class services from pre-clinical through commercial, including:

  • Process development
  • Plasmid DNA
  • Vector manufacturing
  • Cell banking
  • Cell processing
  • A full suite of complementary and standalone testing and analytical capabilities.

Learn more about our newly launched Viral Vector Manufacturing Platform: LentiSure™ and AAVelocity!

At the beginning of April 2023, Yposkesi launched its new Lentiviral Vector Manufacturing Platform, LentiSure.

LentiSure is providing the premium quality grade lentiviral vectors you need to assure your clinical development and commercial cell and gene therapy pipeline. LentiSure’s robust, scalable, and plug & play-optimized processes enable you to accelerate the time to market of your cell and gene therapies and facilitate better patient outcomes. You obtain a safe and effective product through LentiSure’s high productivity and established analytical methods. LentiSure is the choice for high titers, transduction efficiency, reliability, and accessing scalable production processes with optimized purification techniques.


During the conference, our expert Adrien Auffret Cariou, Team Lead Process Development Projects, will make a speaking presentation:

More details soon!

Created by Yerokhoff Kostyiantine